Company intelligence / Profile preview

Exubrion Therapeutics

Alpharetta, Georgia, United Statessynovetin.com ↗

Ownership: Private
Development stage: Commercial

Overview

Synovetin OA has shown significant improvement in clinical trials with 92% of dogs with mild to moderate OA showing improvement and 71% of dogs with more severe OA showing improvement. The treatment provides up to one year of pain relief with a single injection[4][6]

Therapeutic areas: OtherRheumatology
Modalities: Radiotherapeutic technologyTin-117m microparticles
Industry: Veterinary

Drug pipeline

1 asset

Synovetin OA

Commercial

Indications: Canine elbow osteoarthritis

Beyond the preview

Go deeper on Exubrion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exubrion Therapeutics.

Explore the full profile